Objective: To determine whether mastic gum suppresses or eradicates Helicobacter pylori infection in humans.
Introduction
Helicobacter pylori infection is the main cause of peptic ulceration and gastric MALT (mucosa-associated lymphoid tissue) lymphoma and is a major risk factor for development of gastric adenocarcinoma. 1 Mastic gum is a resinous exudate obtained from the stem and the main leaves of Pistacia lentiscus. It is widely used in Middle Eastern and Mediterranean countries as a chewing gum and food additive. We previously reported that mastic is bactericidal against H. pylori in vitro, 2 and this has been independently confirmed. 3 Since then, mastic has been marketed heavily in the UK, other European countries and the USA as a natural treatment for H. pylori infection and peptic ulceration. It is widely available in capsular form in health food shops and over the internet. We now report that mastic has no clinically significant in vivo action against H. pylori in humans.
Materials and methods
To examine whether mastic gum was effective against H. pylori in vivo, we carried out a simple screening study in human volunteer subjects using [ 13 C]urea breath tests (UBTs). Even single doses of antibiotics reduce H. pylori load in the stomach sufficiently to render a UBT temporarily negative. Based on published UBT data, 4 we calculated that we required eight completed subjects to detect a modest reduction in bacterial load with mastic (reduction in UBT value of 2‰) at P < 0.05 (twosided) with 90% power. Thus we recruited nine H. pylori positive patients (by Clotest rapid urease test, Ballard Medical Products, Draper, UT, USA) from our routine day-case endoscopy lists. No patient had current or previous gastroduodenal ulceration, or had taken antibiotics, bismuth compounds or proton pump inhibitors for 6 weeks before the trial. The study was approved by the University Hospital Nottingham Ethics Committee. Patients were treated with mastic capsules 1 g four times daily for 14 days. A [ 13 C]UBT (INFAI, York, UK) was carried out before, on day 15 and 5 weeks after treatment with mastic.
Results and discussion
Eight of the nine patients completed the trial protocol (one withdrew after 5 days of treatment due to nausea and bloating). All eight patients remained H. pylori positive by UBT immediately after finishing mastic treatment, with unchanged UBT values (Figure 1 ; pretreatment mean ± S.E.M. 19.1 ± 3.7‰, post-treatment 18.7 ± 3.8‰, P = 0.8, paired t-test). Eight patients attended for UBT 5 weeks after treatment finished; all remained H. pylori positive, again with unchanged UBT values (Figure 1, 18. 2 ± 3.6‰, P = 0.5 versus pretreatment levels). Other than the patient who withdrew, two patients reported mild adverse symptoms: one complained of fatigue and the second of constipation and bloating.
This preliminary study shows that high dose mastic gum has no clinically significant effect against H. pylori in vivo. Two studies from Iraq have suggested that mastic may be effective for ulcer treatment, but one was uncontrolled 5 and the other seriously flawed:
Mastic gum and H. pylori in vivo blinding was inadequate and analysis was not intention-to-treat. 6 A recent report in this journal 7 showed that mastic monotherapy had no antimicrobial activity against H. pylori in a mouse model. Treatment of H. pylori-associated peptic ulcers should be with anti-acid secretory drugs and H. pylori eradication; this heals ulcers and prevents relapse. 8 Figure 1 . δ Urea breath test values for each of the eight completed volunteer patients before, immediately after and 5 weeks after 2 week treatment with mastic 1 g four times daily. H. pylori negative patients have δ UBT values of less than 3.5‰. Treatment with mastic had no effect on UBT values implying no significant effect on H. pylori load. In comparison, even single doses of antibiotics reduce bacterial load sufficiently to render urea breath tests temporarily negative.
